Problems with the IHC 22C3 assay arise from challenges to pathologist interpretation from limited NSCLC core biopsy specimens; PD-L1 expression can be highly heterogeneous within a given tumor, between primary and metastatic sites, and for different specimen types [9]. The gene discussed is CD274; the disease is neoplasm.